RNXT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.10%

Insider Buying (Last 12 Months): $90,218.50

Insider Selling (Last 12 Months): $0.00

RenovoRx Insider Trading History Chart

RenovoRx Share Price & Price History

^$1.02

▼ -0.01 (-0.97%)

As of 04/17/2025 05:00 PM ET

Days: 30 | 90 | 365

RenovoRx Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/15/2025	Ramtin Agah	Insider	Buy	15,000	$0.90	$13,500.00	1,113,460
4/15/2025	Shaun Bagai	CEO	Buy	7,500	$0.91	$6,825.00	320,040
4/11/2025	Ramtin Agah	Insider	Buy	20,000	$0.80	$16,000.00	1,098,460
4/10/2025	Ron Kocak	VP	Buy	6,500	$0.79	$5,135.00	12,595
4/9/2025	Shaun Bagai	CEO	Buy	10,000	$0.83	$8,300.00	312,540
4/8/2025	Laurence Marton	Director	Buy	12,050	$0.85	$10,242.50	45,684
4/8/2025	Ramtin Agah	Insider	Buy	26,000	$0.84	$21,840.00	1,048,460
4/8/2025	Ron Kocak	VP	Buy	95	$0.80	$76.00	95
4/7/2025	Shaun Bagai	CEO	Buy	10,000	$0.83	$8,300.00	302,540
10/3/2023	Angela Nelms	COO	Buy	1,100	$1.05	$1,155.00	1,100
6/7/2022	Ramtin Agah	Insider	Buy	5,182	$1.93	$10,001.26	6,477
5/19/2022	Shaun Bagai	CEO	Buy	5,500	$2.05	$11,275.00	251,557

See Full Table

SEC Filings (Institutional Ownership Changes) for RenovoRx (NASDAQ:RNXT)

3.10% of RenovoRx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

RenovoRx Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Citadel Advisors LLC	37,757	$49K	0.0%	N/A	0.157%
2/13/2025	Renaissance Technologies LLC	64,900	$84K	0.0%	N/A	0.270%
2/13/2025	ADAR1 Capital Management LLC	197,250	$0.25M	0.1%	-37.4%	0.822%
11/16/2024	Geode Capital Management LLC	232,937	$0.25M	0.0%	+61.9%	0.971%
2/9/2024	Nixon Peabody Trust Co.	97,165	$0.22M	0.0%	N/A	0.909%
7/10/2023	Level Four Advisory Services LLC	15,000	$34K	0.0%	+50.0%	0.148%
6/5/2023	Level Four Advisory Services LLC	10,000	$35K	0.0%	N/A	0.099%
1/19/2023	Affinity Capital Advisors LLC	15,259	$36K	0.0%	+35.6%	0.168%
11/10/2022	Cohen Lawrence B	54,121	$0.16M	0.1%	-44.3%	0.597%
8/11/2022	Cohen Lawrence B	97,165	$0.19M	0.1%	+79.5%	1.072%
8/2/2022	Bank of The West	975,000	$1.93M	0.2%	N/A	10.750%
5/13/2022	Cohen Lawrence B	54,121	$0.16M	0.1%	N/A	0.599%
2/3/2022	Cambridge Investment Research Advisors Inc.	14,400	$70K	0.0%	-64.7%	0.162%
11/16/2021	Schonfeld Strategic Advisors LLC	20,569	$0.13M	0.0%	N/A	0.245%
11/16/2021	Two Sigma Securities LLC	17,944	$0.11M	0.0%	N/A	0.214%
11/12/2021	Board of Trustees of The Leland Stanford Junior University	60,863	$0.37M	0.0%	N/A	0.726%
11/2/2021	Cambridge Investment Research Advisors Inc.	40,850	$0.25M	0.0%	N/A	0.487%

Data available starting January 2016

See Full Table

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Today's Range

Now: $1.02

$0.98

$1.04

50 Day Range

MA: $0.97

$0.77

$1.16

52 Week Range

Now: $1.02

$0.75

$1.69

Volume

109,213 shs

Average Volume

72,792 shs

Market Capitalization

$37.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Who are the company insiders with the largest holdings of RenovoRx?: RenovoRx's top insider shareholders include:
Ramtin Agah (Insider)
Shaun Bagai (CEO)
Laurence Marton (Director)
Ron Kocak (VP)
Angela Nelms (COO)
Learn More about top insider investors at RenovoRx.